Thanks--this is well-articulated. Given the growth and strategy--both organic as well as strategic add-ons--it's safe to assume that what you're buying today in theory will look v different from tomorrow and therefore v difficult to peg a good multiple, especially if the acquisitions are highly accretive (noted however, buying growth is v different than organic for obvious reasons).
Also challenging bc there are decent precedents where the multiple is alot higher. As example, FIZZ trades at 4x fwd rev growing at 15% (LTM) and 15x+ EBITDA and while they are killing it, it's still a (good for you) CSD.
health/wellness products like pediade should get a HC multiple--never really been done before
But agree the 3x run-rate is a good governor for sanity purposes